ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Biological Chemistry

Amyris to revise artemisinin route

by Melody M. Bomgardner
April 18, 2016 | APPEARED IN VOLUME 94, ISSUE 16

[+]Enlarge
Credit: Amyris
An Amyris researcher examines genetically modified microbes under a microscope.
Credit: Amyris
An Amyris researcher examines genetically modified microbes under a microscope.

Industrial biotechnology firm Amyris will work to reduce the cost of making the malaria treatment artemisinin via fermentation with help from a $5 million investment from the Bill & Melinda Gates Foundation. The company first developed its biotech route to the drug in 2005. The product is also derived from the herb sweet wormwood, but supplies are subject to shortages.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment